STADA CIS

Assets

Russian holding STADA CIS is engaged in the development, production and sale of medicines in the CIS and Baltic countries, is a member of the international STADA Group.

The holding's parent company for 2010 is Nizhfarm, whose tasks include planning, consolidation of statements, as well as analysis of the activities of the holding's companies:

• NIZHFARM (Nizhny Novgorod) - a global center of competencies in soft forms,
• MAKIZ-PHARMA (d Moscow.),
• SKOPINFARM (Ryazan region) - production;
• STADA Marketing,
• STADA Ukraine,
• STADA Central Asia,
• STADA Azerbaidjan,
• STADA Armenia - marketing, sale and distribution of products; * STADA PharmDevelopment - R&D division.

In 2022, Chemofarm (STADA CIS) was also mentioned among the assets in Obninsk with a focus on the production of solid dosage forms.

History

2021: Russia accounted for 15% of STADA's total turnover

At the end of 2021, STADA in Russia, the company showed significant growth: the region accounted for about 15% of the total turnover of STADA in 2021. STADA in Russia has shown significant growth both in the Consumer HealthCare segment and in the prescription drug segment.

STADA in Russia has one of the deepest levels of localization among international pharmaceutical companies - more than 65%.

2021: Appointment of Alexander Samorodov as IT Director

From February 1, 2021, Alexander Samorodov took the position of Stada Information Technology Director in Russia and the CIS. Alexander came to Stada from Alcon, a manufacturer of drugs and medical products, where he served as head of the IT department in Russia. This was announced on February 1, 2021 by TAdviser at Stada. More details here.

2020

Blocking delivery of 1.5 million products due to labeling system failure

On November 25, 2020, it became known that Russian customs blocked the supply of 1.5 million Stada products due to a failure of the marking system.

If you introduce products and data from the FGIS MDLP into civil circulation [the federal state system for monitoring the movement of drugs - approx. Zdrav.expert] did not fully enter the AIS Roszdravnadzor, then this also blocks the further movement of drugs, despite Government Decree No. 1779 on the notification regime, "said Stada Artem Selem, head of the department for monitoring the movement of finished products.

Customs blocked the supply of 1.5 million Stada products due to a failure of the labeling system

On November 24, 2020, Deputy Prime Minister Tatyana Golikova, speaking at a meeting of the coordinating council of human rights commissioners, noted that when hype demand began in pharmacies, planned work on labeling medicines became impossible due to a system failure. After that, the Government of the Russian Federation decided to switch to labeling medicines in a notification order.

According to the information that we currently have from the constituent entities of the Russian Federation, this topic as a possible restriction on the presence of drugs in pharmacies is almost removed, "she said on November 24.

Stada asks to extend the notification regime until the transition to data transfer to the system on a voluntary basis, leaving mandatory requirements for labeling and the transfer of information on the disposal of labeled drugs. The company proposed to establish an exchange of data between the information system of the Federal Customs Service and the FGIS MDLP, as well as between the AIS Roszdravnadzor and the FGIS MDLP. Then importers in Russia would not have to transfer additional information to the FSIS about the results of customs clearance, and local manufacturers and importers about the introduction of products into civil circulation.

Artem Selyansky recalled the rules of fair competition between Russian and foreign producers. Domestic producers and importers are required to transfer significantly more voluminous data than from foreign ones, he explained.^[1]

Plan to invest €13 million in increasing the capacity of Russian pharmaceutical enterprises

In September 2020, it was announced that Stada plans to invest €13 million in increasing the capacity of Russian pharmaceutical enterprises within three years.

"Over the past 15 years, the company's total direct investment amounted to almost €1 billion. Stada sees great potential in Russian production and seeks to make the most of it. The company has one of the deepest levels of localization - more than 70% and continues to invest in this direction. "

Stada notes that direct investments of international pharmaceutical companies in Russia over the period of 2010-2019 amounted to about 241 billion rubles, the total contribution (taking into account labor costs and the total indirect impact on the development of the Russian economy) of international pharmaceutical companies to the Russian economy over the past 10 years exceeds 1.2 trillion rubles.

Appointment of Arminas Matsevičius as Head of Stada CIS

On July 13, 2020, Stada appointed a new head for the CIS countries. He became Arminas Matsevičius, who previously held a similar position in Takeda, heading the cluster of Central Asia and the Caucasus. More details here.

Notes